News

The new medicine, which is available online at Dietonliner.com, has been prepared from extracts of pure natural herbal compounds as well as several types of vitamins and minerals

Based on the agreement, Immunocore will get up to £142m in pre-clinical milestone payments across the targets and £200m in development and commercial milestone payments, including up to

The FDA approved Qutenza is for neuropathic pain management related with postherpetic neuralgia, while NP-1998 is a Phase 3 ready, prescription strength capsaicin topical solution under evaluation to

Lucentis is a humanized therapeutic antibody fragment designed to block all biologically active forms of vascular endothelial cell growth factor-A (VEGF-A). The first anti-VEGF therapy, Lucentis is intended

The supply agreement follows the development and scale-up of a new affinity resin, which is intended to develop the quality and purity of an existing biopharmaceutical product. The

Pixuvri has been approved as a monotherapy to treat adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma, including those with aggressive B-cell NHL who failed

The application has been filed through the EMA’s biosimilar pathway for the investigational basal (long-acting) insulin to treat type 1 and type 2 diabetes. Lilly Diabetes product development

Care’s brands include the Fess line of cold/allergy and saline nasal health products, Painstop analgesic, Rectogesic for rectal discomfort, and the Fab line of nutritional supplements. Financial details

This announcement comes, following a strategic alliance inked on 26 June 2013 between Cha and Pluristem Therapeutics, which is a developer of placenta-based cell therapies. As per the